

BIO DEUTSCHLAND

European Business Development Conference

7 – 8 October 2014 | Dresden | Germany

Frank Schnieders

Dr Frank Schnieders is founder and CEO of Provecs Medical, Hamburg, Germany, a biopharmaceutical company specialized in cancer immunotherapy. Provecs' ENVIRO technology is unique in targeting and reprogramming the cancer microenvironment by combinations of key immunological signal proteins. The first preclinical product candidate Immunalon® has been partnered and is currently developed in a pharma collaboration.

Dr Schnieders expertise is based on more than 15 years in biotechnology, entrepreneurship, research & development, intellectual properties, corporate finance and strategy.

Since 2007 he is responsible for the successful spin-out, financing, and positioning of Provecs Medical. Dr. Schnieders is an active member of various biotech networks, including the Cancer Immunotherapy Consortium, Life Science Nord e.V., BioDeutschland, and Science4Life.

He studied biochemistry in Cologne and Hannover and holds a PhD in Human Genetics from the Medical School in Hannover. He focused his scientific work on the field of Gene Therapy at the Max-Planck Gesellschaft, the Max-Delbrück-Center for Molecular Medicine in Berlin, the Heinrich-Pette Institute for Experimental Virology, Hamburg, and the University Medical Center Hamburg-Eppendorf. He is author of numerous scientific publications and inventor of two patent families.